Survival Is Related to Estrogen Signal Transduction Pathway Activity in Postmenopausal Women Diagnosed with High-Grade Serous Ovarian Carcinoma.
estrogen signaling
ovarian cancer
signal transduction pathways
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
12 Oct 2021
12 Oct 2021
Historique:
received:
30
08
2021
revised:
29
09
2021
accepted:
05
10
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
24
10
2021
Statut:
epublish
Résumé
High-grade serous ovarian carcinoma (HGSC), the most common subtype of ovarian cancer, has a high mortality rate. Although there are some factors associated with survival, such as stage of disease, there are remarkable differences in survival among women diagnosed with advanced stage disease. In this study, we investigate possible relations between survival and signal transduction pathway (STP) activity. We assessed the functional activity of the androgen receptor (AR), estrogen receptor (ER), phosphoinositide-3-kinase (PI3K), Hedgehog (HH), transforming growth factor beta (TGF-β) and canonical wingless-type MMTV integration site (Wnt) pathway in 85 primary tumor samples of patients with FIGO stage IIIC to IVB HGSC and disease-free survival (DFS) below 12 (
Identifiants
pubmed: 34680250
pii: cancers13205101
doi: 10.3390/cancers13205101
pmc: PMC8533979
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ruby and Rose Foundation
ID : R0004286
Organisme : Catharina Research Fund
Organisme : Molecular Pathway Diagnostics, Philips
Références
Front Oncol. 2020 Oct 23;10:587386
pubmed: 33194742
Lancet Oncol. 2013 Aug;14(9):853-62
pubmed: 23845225
Oncotarget. 2017 May 29;8(37):62400-62413
pubmed: 28977954
Cell Signal. 2015 Mar;27(3):510-8
pubmed: 25578861
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Sci Rep. 2019 Feb 7;9(1):1603
pubmed: 30733525
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Cancers (Basel). 2020 Sep 18;12(9):
pubmed: 32961868
Gynecol Oncol. 2020 Apr;157(1):209-213
pubmed: 31952843
Gynecol Oncol. 2016 May;141(2):260-263
pubmed: 26968641
Am J Pathol. 2018 Sep;188(9):1956-1972
pubmed: 30030980
Gynecol Oncol. 2009 Dec;115(3):401-6
pubmed: 19796795
Gynecol Oncol. 2018 Feb;148(2):275-280
pubmed: 29195926
Cancer Res. 2014 Jun 1;74(11):2936-45
pubmed: 24695361
Am J Obstet Gynecol. 2019 Oct;221(4):326.e1-326.e7
pubmed: 31082382
Br J Cancer. 2020 Sep;123(5):793-802
pubmed: 32555365
Cancer Lett. 2006 Jan 18;231(2):151-7
pubmed: 16399219
Br J Cancer. 2020 Sep;123(5):785-792
pubmed: 32507853
Mol Cancer Ther. 2020 Feb;19(2):680-689
pubmed: 31727690
Adv Protein Chem Struct Biol. 2019;116:135-170
pubmed: 31036290
Gynecol Oncol. 2015 Sep;138(3):634-9
pubmed: 26115976
Oncotarget. 2014 Jul 30;5(14):5196-7
pubmed: 25114037
Cancers (Basel). 2019 Jul 30;11(8):
pubmed: 31366178
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:93-108
pubmed: 30306579
Science. 1989 May 12;244(4905):707-12
pubmed: 2470152
Clin Breast Cancer. 2004 Apr;5(1):63-9
pubmed: 15140287
Cancer Cell. 2011 May 17;19(5):575-86
pubmed: 21575859
Front Genet. 2021 Feb 05;11:598118
pubmed: 33613616
Tumori. 2009 Mar-Apr;95(2):207-11
pubmed: 19579867
Gynecol Oncol. 2018 Jan;148(1):204-212
pubmed: 29128106
Front Endocrinol (Lausanne). 2014 Nov 12;5:192
pubmed: 25429284
Cancer Res. 2007 Jan 1;67(1):75-84
pubmed: 17210685
Oncol Lett. 2017 Jun;13(6):4047-4054
pubmed: 28588698
Cancers (Basel). 2019 Mar 01;11(3):
pubmed: 30832253
Cell Oncol (Dordr). 2021 Aug;44(4):951-957
pubmed: 33723801
Clin Cancer Res. 2008 Aug 15;14(16):5198-208
pubmed: 18698038